查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1856658

豬疫苗市場（按疫苗類型、適應症、最終用戶、給藥途徑、技術和劑型分類）－全球預測，2025-2032年

Porcine Vaccines Market by Vaccine Type, Disease Indication, End User, Route Of Administration, Technology, Dosage Form - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，豬隻疫苗市場規模將成長 31.2 億美元，複合年成長率為 6.98%。

關鍵市場統計數據
基準年 2024 18.2億美元
預計年份：2025年 19.4億美元
預測年份 2032 31.2億美元
複合年成長率 (%) 6.98%

清晰權威地介紹了近期科學、監管和商業趨勢如何重新定義豬疫苗研發的優先事項。

由於科學創新、生產模式演變和農場需求變化等因素的交匯，豬疫苗領域正處於曲折點。核酸技術的進步、佐劑配方的改進以及更先進的給藥途徑正在改變人們對產品性能的預期和研發路徑。同時，監管機構正在更新關於新型平台和生產品質框架的指導意見，要求研發人員和生產商更靈活地調整其臨床開發計畫和生產控制措施。

平台創新、監測情報和以現場為中心的交付方式的融合如何推動豬疫苗策略的系統性變革

隨著平台技術和疾病標靶策略的日趨成熟，豬免疫學領域正從漸進式產品改進轉向結構性變革。基於RNA的製劑、重組表現系統和病毒載體正與改良的佐劑和製劑技術結合，從而加速抗原發現和適應性生產。這種技術融合正在縮短病原體鑑定到候選藥物開發之間的時間間隔，進而改變企業規劃產品線和分配研發資源的方式。

對2025年美國關稅政策變化所引發的連鎖營運和採購影響進行全面分析

美國2025年宣布的關稅政策調整對豬隻疫苗相關人員的採購、供應鏈經濟和戰略採購產生了多方面的影響。某些生技藥品和生產耗材關稅的提高增加了依賴國際原料供應的供應商的投入成本，進而影響了製造商和合約服務提供者的定價策略和供應商選擇。這促使許多公司重新評估其供應商佈局，並加快國內或區域替代供應商的資格認證，以降低關稅波動帶來的風險。

將疫苗平台、目標疾病、終端用戶需求、給藥途徑、生產技術和劑型與策略重點連結起來的綜合細分分析

這種細緻的細分框架揭示了疫苗類型、適應症、最終用戶、給藥途徑、技術和劑型在產品開發、部署策略和最終用戶接受度方面的差異。疫苗類型，包括去活化疫苗、減毒疫苗、mRNA構建體、次單位疫苗和病毒載體製劑，其開發週期和監管考量各不相同。例如，去活化疫苗有裂解病毒、亞細胞和全病毒製劑，而減毒疫苗則根據異源和同源設計方案進行區分。 mRNA製劑需要根據其是否為非複製型或自擴增型進行不同的最佳化，而次單位疫苗則需要在次單元單位策略和蛋白質次單元策略之間進行選擇。病毒載體平台可採用腺病毒或痘病毒載體骨架，每種載體在免疫學和生產方面各有優劣。

亞太、歐洲和中東地區的區域策略挑戰將決定豬疫苗的監管、分發和推廣路徑。

區域動態對研究重點、監管策略和商業化途徑的形成至關重要。在美洲，大型商業營運和完善的獸醫服務網路推動了對先進平台解決方案和精準疫苗接種策略的需求，而監管重點則放在生產品質和上市後監測上，從而形成了一個異質性生態系統。相較之下，歐洲、中東和非洲的法律規範和基礎設施差異顯著，因此需要能夠適應高度監管市場以及低溫運輸和獸醫服務能力有限的地區的靈活商業化模式。亞太地區某些中心城市創新應用迅速，而其他地區則擁有龐大的小農戶群體，因此需要採取雙軌制策略，在部署高科技平台的同時，兼顧成本效益高、便於田間使用的疫苗方案。

創新主導開發商、契約製造和策略夥伴如何塑造豬疫苗價值鏈中的競爭差異化

競爭格局呈現出由成熟的動物用藥品公司、專業生物技術創新企業、受託製造廠商)和學術研究中心組成的多元化格局。規模較大的研發企業優先考慮平台多元化，以平衡近期商業化產品和長期在臨床實驗藥物，並經常尋求將臨床開發實力與可擴展生產技術相結合的夥伴關係。契約製造和 CDMO 的角色日益重要，它們使較小的創新企業能夠獲得符合 GMP 標準的生產，並使大型企業能夠在不過度投資固定資產的情況下靈活管理產能。

為開發人員和相關人員提供切實有效的策略建議，以加快豬疫苗領域的平台準備、供應鏈彈性以及終端用戶採納率。

產業領導者應採取三管齊下的策略方針，將科學研究能力與營運韌性和市場進入便利化結合。例如，在維持最佳化傳統產品線的同時，擴大RNA和重組DNA技術能力，既能快速應對新出現的威脅，也能確保在疫情期間產品的穩定供應。其次，為降低貿易中斷和關稅導致的成本波動風險，應透過尋找替代原料來源、投資區域生產或填充加工能力以及加強低溫運輸基礎設施來建立供應鏈韌性。

一種嚴謹的多資訊來源調查方法，結合了專家訪談、監管機構研究、科學文獻綜述和基於情境的供應鏈分析。

該研究結合了定性和定量數據，包括科學文獻、監管指導文件、行業披露資訊、技術簡報以及對價值鏈各環節專家的訪談。證據綜合分析優先考慮了平台免疫學和製劑科學的同行評審研究、與生物製藥和新產品相關的監管指南，以及來自生產和分銷相關人員的營運文件，從而全面觀點技術、供應和應用趨勢。

綜合各項結論，強調技術融合、供應鏈韌性和協作方法是未來豬隻免疫學發展的基礎。

豬疫苗生態系統日益受到創新、務實和不斷變化的政策環境三者相互作用的影響。平台技術的進步為提高疫苗的保護範圍和反應速度提供了切實的機會，但要實現這些益處，需要同步投資於生產靈活性、監管策略和現場供給能力。同時，貿易政策的變化和供應鏈壓力凸顯了地域多元化和供應商合格對於保障供應連續性和控制成本風險的重要性。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 先進的mRNA疫苗平台因其能夠快速控制豬傳染病而越來越受歡迎。
  • 將新型奈米顆粒佐劑整合到豬流感疫苗中以提高其效力
  • 政府資助計畫旨在加速非洲豬瘟疫苗的商業化進程
  • 一家生物技術企業與一家大型動物用藥品公司建立策略夥伴關係，共同開發下一代豬用疫苗
  • 引入數位化診斷工具，用於在接種疫苗前即時監測豬群的免疫狀態。
  • 隨著生豬養殖規模的擴大，對能夠預防多種豬呼吸道病原體的廣譜多效價疫苗的需求日益成長。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依疫苗類型分類的豬隻疫苗市場

  • 惰性
    • 分裂病毒
    • 亞細胞
    • 整個病毒
  • 活病毒疫苗
    • 異質
    • 同源
  • MRNA
    • 未擴增的mRNA
    • 自擴增mRNA
  • 次單元
    • 多醣體次單元
    • 蛋白質次單元
  • 病毒載體
    • 腺病毒載體
    • 痘病毒載體

9. 依適應症分類的豬隻疫苗市場

  • 傳統豬瘟
  • 丹毒
  • 豬繁殖與呼吸綜合症
  • 豬流感

第10章 以最終用戶分類的豬隻疫苗市場

  • 商業農場
  • 研究所
  • 小農場
  • 獸醫診所

第11章 依給藥途徑分類的豬隻疫苗市場

  • 皮內注射
  • 肌肉內注射
  • 鼻腔
  • 口服
  • 皮下

12. 按技術分類的豬隻疫苗市場

  • 傳統的
    • 減毒活病毒疫苗
    • 基爾德霍爾
  • DNA
  • 重組
    • 細菌表達
    • 昆蟲細胞表達
    • 酵母表達
  • RNA
  • VLP

第13章 豬疫苗市場按劑型分類

  • 乳液
  • 液體
  • 冷凍乾燥

第14章 各地區豬隻疫苗市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 豬疫苗市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國豬疫苗市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Zoetis Inc.
    • Boehringer Ingelheim International GmbH
    • Merck & Co., Inc.
    • Ceva Sante Animale SA
    • Elanco Animal Health Incorporated
    • HIPRA, SA
    • Vetoquinol SA
    • Phibro Animal Health Corporation
    • Virbac SA
    • Bioveta, as
Product Code: MRR-742BD5183CF6

The Porcine Vaccines Market is projected to grow by USD 3.12 billion at a CAGR of 6.98% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.82 billion
Estimated Year [2025] USD 1.94 billion
Forecast Year [2032] USD 3.12 billion
CAGR (%) 6.98%

A clear, authoritative primer explaining how recent scientific, regulatory, and operational changes are redefining priorities in porcine vaccine development

The porcine vaccine arena stands at an inflection point driven by converging scientific innovation, evolving production modalities, and shifting farm-level needs. Advances in nucleic acid technologies, improved adjuvant formulations, and more refined delivery routes have altered both product performance expectations and development pathways. Meanwhile, regulatory authorities are updating guidance on novel platforms and manufacturing quality frameworks, which requires developers and producers to adapt clinical development plans and manufacturing controls with greater agility.

Operational pressures across supply chains and the increasing focus on biosafety and traceability are reshaping procurement practices among commercial farms, veterinary hospitals, and research institutes. As stakeholders prioritize resilience and predictability, there is a growing premium on vaccines that combine robust efficacy profiles with simplified administration and storage requirements. Collectively, these dynamics are redefining investment priorities, strategic partnerships, and pipeline development across the sector.

How converging platform innovations, surveillance intelligence, and field-centric delivery approaches are driving systemic transformation in porcine vaccine strategies

The landscape for porcine immunization is moving from incremental product improvement toward structural transformation as platform technologies and disease targeting strategies mature. RNA-based modalities, recombinant expression systems, and viral vectors are converging with improved adjuvant and formulation science to enable faster antigen discovery and adaptable manufacturing. This technological convergence shortens the interval between pathogen identification and candidate deployment, thereby changing how companies plan pipelines and allocate R&D resources.

Concurrently, disease surveillance networks and data integration across farms and veterinary services are enabling earlier outbreak detection and more precise vaccine deployment strategies. These capabilities are encouraging stakeholders to invest in modular production capacity, cold chain innovations, and alternative routes of administration that reduce labor and stress at the herd level. As a result, strategic emphasis is shifting toward platform flexibility, cross-protection potential, and ease of field use, which together are driving new collaboration models between developers, contract manufacturers, and end users.

Comprehensive analysis of the cascading operational and sourcing consequences that resulted from the United States tariff changes implemented in 2025

US tariff policy changes announced in 2025 have had multifaceted implications across sourcing, supply chain economics, and strategic procurement for porcine vaccine stakeholders. Increased duties on selected biologics inputs and certain manufacturing consumables elevated input costs for suppliers that rely on international raw material flows, which in turn influenced pricing strategies and vendor selection for manufacturers and contract service providers. In response, many organizations reassessed supplier footprints and accelerated qualification of alternative domestic or regional suppliers to reduce exposure to tariff variability.

These adjustments also pushed manufacturers to evaluate inventory policies and to strengthen contractual terms with upstream suppliers to secure supply continuity. For end users such as commercial farms and veterinary networks, procurement practices evolved toward longer-term purchasing agreements and collaborative planning to smooth supply disruptions. Policymakers and industry groups engaged in dialogue to clarify tariff scope and to explore mitigations, including targeted exemptions, streamlined customs processes, and incentives for local production capacity to reinforce resilience and hedging against future trade volatility.

An integrated segmentation analysis linking vaccine platforms, disease targets, end-user needs, administration routes, production technologies, and dosage formats to strategic priorities

A nuanced segmentation framework reveals how product development, deployment strategies, and end-user uptake diverge across vaccine type, disease indication, end user, route of administration, technology, and dosage form. Vaccine type distinctions between Inactivated formats, Live Attenuated preparations, mRNA constructs, Subunit vaccines, and Virus Vectored solutions shape development timelines and regulatory considerations; for example, Inactivated vaccines vary further as Split Virus, Subcellular, and Whole Virus formulations, while Live Attenuated approaches are differentiated by Heterologous and Homologous design choices. mRNA modalities require different optimization depending on whether they are Non-Amplifying or Self-Amplifying constructs, and Subunit vaccines call for choices between Polysaccharide Subunit and Protein Subunit strategies. Virus Vectored platforms may leverage Adenovirus Vector or Poxvirus Vector backbones, each with distinct immunologic and manufacturing trade-offs.

Disease indication segmentation including Classical Swine Fever, Erysipelas, Porcine Reproductive And Respiratory Syndrome, and Swine Influenza directs antigen selection priorities and field trial design. End users such as Commercial Farms, Research Institutes, Smallholder Farms, and Veterinary Hospitals present contrasting adoption criteria that influence dosing regimens, packaging, and service models. Route of administration choices spanning Intradermal, Intramuscular, Intranasal, Oral, and Subcutaneous determine product format and on-farm labor implications. Underlying technology categories of Conventional, DNA, Recombinant, RNA, and VLP further shape development pathways, with Conventional pathways subdividing into Attenuated Live and Killed Whole approaches and Recombinant strategies differentiating between Bacteria Expressed, Insect Cell Expressed, and Yeast Expressed production methods. Dosage form variants across Emulsion, Liquid, and Lyophilized formats affect logistics and shelf-life considerations. Taken together, this segmentation matrix clarifies where technical investment and commercialization focus will yield the greatest operational and clinical impact.

Regional strategic imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific that determine regulatory, distribution, and adoption pathways for porcine vaccines

Regional dynamics are critical for shaping research priorities, regulatory strategy, and commercialization approaches. The Americas present a heterogeneous ecosystem in which large commercial operations and sophisticated veterinary service networks drive demand for advanced platform solutions and precision immunization strategies, while regulatory scrutiny emphasizes manufacturing quality and post-licensure surveillance. In contrast, Europe, Middle East & Africa exhibits wide variability across regulatory frameworks and infrastructure, requiring adaptable commercialization models that can accommodate both highly regulated markets and areas with more constrained cold chain or veterinary services capacity. Asia-Pacific combines rapid innovation adoption in certain hubs with extensive smallholder populations in other geographies, necessitating a dual-track approach that balances high-tech platform deployment alongside cost-effective, field-friendly vaccine options.

These regional contrasts influence R&D prioritization, partnership models, and distribution strategies. For developers and suppliers, success depends on tailoring dossiers and evidence packages to regulatory expectations in each region while designing logistics and service models that match local end-user capabilities. Consequently, strategic regional investments in manufacturing, cold chain enhancements, and localized training programs can materially affect uptake and long-term adoption trajectories across geographies.

How innovation-led developers, contract manufacturers, and strategic collaborations are shaping competitive differentiation across the porcine vaccine value chain

The competitive landscape is characterized by a mix of established animal health corporations, specialized biotech innovators, contract manufacturing organizations, and academic research centers. Leading developers emphasize platform diversification to balance near-term commercial products with longer-term investigational candidates, often pursuing partnerships that combine clinical development strength with scalable manufacturing expertise. Contract manufacturers and CDMOs are playing an increasingly pivotal role, enabling smaller innovators to access GMP-compliant production and allowing larger firms to manage capacity flexibility without over-investing in fixed assets.

Strategic behaviors among companies include vertical integration of supply chains, targeted acquisitions to close capability gaps in novel platforms, and collaborative research agreements that accelerate antigen discovery and immunogenicity testing. Firms that invest in robust regulatory affairs teams and post-approval surveillance capabilities achieve smoother product rollouts and stronger stakeholder trust. Meanwhile, companies prioritizing field-centric design-such as simplified dosing regimens, thermostable formulations, and minimally invasive delivery-are better positioned to capture adoption among diverse end users. Overall, sustained competitive advantage arises from the intersection of scientific excellence, manufacturing resilience, and deep understanding of end-user operational needs.

High-impact, practical strategic recommendations for developers and stakeholders to accelerate platform readiness, supply resilience, and end-user adoption in the porcine vaccine sector

Industry leaders should adopt a three-pronged strategic approach that aligns scientific capability with operational resilience and market access facilitation. First, prioritize platform investments that deliver both agility and breadth; for example, expanding RNA and recombinant capabilities while maintaining optimized conventional pipelines can enable both rapid response to emergent threats and stable product offerings for endemic diseases. Second, build supply chain resilience by qualifying alternative raw material sources, investing in regional production or fill-finish capacity, and enhancing cold chain infrastructure to reduce vulnerability to trade disruptions and tariff-induced cost shifts.

Third, strengthen end-user engagement by co-developing administration and training programs with veterinary networks and farm groups so that product attributes are matched to field realities. In parallel, pursue regulatory engagement early in development to align on evidence requirements for novel platforms and to expedite approval pathways. Finally, consider flexible commercial models such as subscription-style supply agreements or tiered pricing to expand reach across different end-user segments while maintaining sustainable revenue streams. These combined actions will help organizations convert scientific advances into reliable, accessible immunization solutions.

A rigorous, multi-source research methodology integrating primary expert interviews, regulatory review, scientific literature synthesis, and scenario-based supply chain analysis

This research synthesized qualitative and quantitative inputs across scientific literature, regulatory guidance documents, industry disclosures, technical briefings, and interviews with subject-matter experts across the value chain. Evidence synthesis prioritized peer-reviewed studies on platform immunology and formulation science, regulatory guidelines relevant to biologicals and novel modalities, and operational documentation from manufacturing and distribution stakeholders to create a comprehensive perspective on technology, supply, and adoption trends.

In addition to secondary research, primary engagements included structured interviews with laboratory researchers, manufacturing leaders, regulatory affairs professionals, and farm-level practitioners to validate assumptions and surface practical adoption barriers. Triangulation techniques were used to reconcile differing viewpoints and to ensure that conclusions reflect both scientific plausibility and operational feasibility. Analytic methods emphasized thematic coding for qualitative inputs and scenario analysis for supply chain and policy impact assessment, thereby providing robust, actionable insights for decision-makers.

Concluding synthesis emphasizing technology convergence, supply resilience, and collaborative approaches as the foundations for future progress in porcine immunization

The porcine vaccine ecosystem is increasingly defined by the interplay of technological innovation, operational pragmatism, and evolving policy environments. Advances in platform technologies offer genuine opportunities to improve protection breadth and speed of response, but realizing those gains requires synchronized investment in manufacturing flexibility, regulatory strategy, and field delivery capabilities. In parallel, trade policy shifts and supply chain pressure underscore the importance of regional diversification and supplier qualification to protect continuity of supply and to manage cost exposure.

Going forward, stakeholders that combine platform agility with deep end-user engagement and resilient supply arrangements will be best positioned to convert scientific progress into measurable animal health outcomes. Cross-sector collaboration-spanning developers, service providers, regulators, and farm networks-will remain essential to accelerate responsible adoption and to ensure that innovations translate into sustainable improvements in disease control and farm productivity.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Advanced mRNA vaccine platforms gaining traction for rapid porcine disease control
  • 5.2. Integration of novel nanoparticle adjuvants to enhance porcine influenza vaccine efficacy
  • 5.3. Government funding initiatives accelerating African swine fever vaccine commercialization efforts
  • 5.4. Strategic partnerships between biotech startups and major animal health companies to co-develop next-generation porcine vaccines
  • 5.5. Adoption of digital diagnostic tools for real-time monitoring of porcine herd immune status before vaccination
  • 5.6. Rising demand for broad-spectrum multivalent vaccines targeting multiple swine respiratory pathogens in growing herds

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Porcine Vaccines Market, by Vaccine Type

  • 8.1. Inactivated
    • 8.1.1. Split Virus
    • 8.1.2. Subcellular
    • 8.1.3. Whole Virus
  • 8.2. Live Attenuated
    • 8.2.1. Heterologous
    • 8.2.2. Homologous
  • 8.3. MRNA
    • 8.3.1. Non Amplifying MRNA
    • 8.3.2. Self Amplifying MRNA
  • 8.4. Subunit
    • 8.4.1. Polysaccharide Subunit
    • 8.4.2. Protein Subunit
  • 8.5. Virus Vectored
    • 8.5.1. Adenovirus Vector
    • 8.5.2. Poxvirus Vector

9. Porcine Vaccines Market, by Disease Indication

  • 9.1. Classical Swine Fever
  • 9.2. Erysipelas
  • 9.3. Porcine Reproductive And Respiratory Syndrome
  • 9.4. Swine Influenza

10. Porcine Vaccines Market, by End User

  • 10.1. Commercial Farm
  • 10.2. Research Institute
  • 10.3. Smallholder Farm
  • 10.4. Veterinary Hospital

11. Porcine Vaccines Market, by Route Of Administration

  • 11.1. Intradermal
  • 11.2. Intramuscular
  • 11.3. Intranasal
  • 11.4. Oral
  • 11.5. Subcutaneous

12. Porcine Vaccines Market, by Technology

  • 12.1. Conventional
    • 12.1.1. Attenuated Live
    • 12.1.2. Killed Whole
  • 12.2. DNA
  • 12.3. Recombinant
    • 12.3.1. Bacteria Expressed
    • 12.3.2. Insect Cell Expressed
    • 12.3.3. Yeast Expressed
  • 12.4. RNA
  • 12.5. VLP

13. Porcine Vaccines Market, by Dosage Form

  • 13.1. Emulsion
  • 13.2. Liquid
  • 13.3. Lyophilized

14. Porcine Vaccines Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Porcine Vaccines Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Porcine Vaccines Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Zoetis Inc.
    • 17.3.2. Boehringer Ingelheim International GmbH
    • 17.3.3. Merck & Co., Inc.
    • 17.3.4. Ceva Sante Animale S.A.
    • 17.3.5. Elanco Animal Health Incorporated
    • 17.3.6. HIPRA, S.A.
    • 17.3.7. Vetoquinol S.A.
    • 17.3.8. Phibro Animal Health Corporation
    • 17.3.9. Virbac S.A.
    • 17.3.10. Bioveta, a.s.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PORCINE VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PORCINE VACCINES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PORCINE VACCINES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PORCINE VACCINES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS PORCINE VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL PORCINE VACCINES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. PORCINE VACCINES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. PORCINE VACCINES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PORCINE VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PORCINE VACCINES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PORCINE VACCINES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PORCINE VACCINES MARKET SIZE, BY SPLIT VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PORCINE VACCINES MARKET SIZE, BY SPLIT VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PORCINE VACCINES MARKET SIZE, BY SPLIT VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PORCINE VACCINES MARKET SIZE, BY SPLIT VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PORCINE VACCINES MARKET SIZE, BY SPLIT VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PORCINE VACCINES MARKET SIZE, BY SPLIT VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCELLULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCELLULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCELLULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCELLULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCELLULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCELLULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PORCINE VACCINES MARKET SIZE, BY WHOLE VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PORCINE VACCINES MARKET SIZE, BY WHOLE VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PORCINE VACCINES MARKET SIZE, BY WHOLE VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PORCINE VACCINES MARKET SIZE, BY WHOLE VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PORCINE VACCINES MARKET SIZE, BY WHOLE VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PORCINE VACCINES MARKET SIZE, BY WHOLE VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PORCINE VACCINES MARKET SIZE, BY HETEROLOGOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PORCINE VACCINES MARKET SIZE, BY HETEROLOGOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PORCINE VACCINES MARKET SIZE, BY HETEROLOGOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PORCINE VACCINES MARKET SIZE, BY HETEROLOGOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PORCINE VACCINES MARKET SIZE, BY HETEROLOGOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PORCINE VACCINES MARKET SIZE, BY HETEROLOGOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PORCINE VACCINES MARKET SIZE, BY HOMOLOGOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PORCINE VACCINES MARKET SIZE, BY HOMOLOGOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PORCINE VACCINES MARKET SIZE, BY HOMOLOGOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PORCINE VACCINES MARKET SIZE, BY HOMOLOGOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PORCINE VACCINES MARKET SIZE, BY HOMOLOGOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PORCINE VACCINES MARKET SIZE, BY HOMOLOGOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PORCINE VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PORCINE VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PORCINE VACCINES MARKET SIZE, BY MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PORCINE VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PORCINE VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PORCINE VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PORCINE VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PORCINE VACCINES MARKET SIZE, BY NON AMPLIFYING MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PORCINE VACCINES MARKET SIZE, BY NON AMPLIFYING MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PORCINE VACCINES MARKET SIZE, BY NON AMPLIFYING MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PORCINE VACCINES MARKET SIZE, BY NON AMPLIFYING MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PORCINE VACCINES MARKET SIZE, BY NON AMPLIFYING MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PORCINE VACCINES MARKET SIZE, BY NON AMPLIFYING MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PORCINE VACCINES MARKET SIZE, BY SELF AMPLIFYING MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PORCINE VACCINES MARKET SIZE, BY SELF AMPLIFYING MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PORCINE VACCINES MARKET SIZE, BY SELF AMPLIFYING MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PORCINE VACCINES MARKET SIZE, BY SELF AMPLIFYING MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PORCINE VACCINES MARKET SIZE, BY SELF AMPLIFYING MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PORCINE VACCINES MARKET SIZE, BY SELF AMPLIFYING MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PORCINE VACCINES MARKET SIZE, BY POLYSACCHARIDE SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PORCINE VACCINES MARKET SIZE, BY POLYSACCHARIDE SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PORCINE VACCINES MARKET SIZE, BY POLYSACCHARIDE SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PORCINE VACCINES MARKET SIZE, BY POLYSACCHARIDE SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PORCINE VACCINES MARKET SIZE, BY POLYSACCHARIDE SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PORCINE VACCINES MARKET SIZE, BY POLYSACCHARIDE SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PORCINE VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PORCINE VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PORCINE VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PORCINE VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PORCINE VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PORCINE VACCINES MARKET SIZE, BY PROTEIN SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PORCINE VACCINES MARKET SIZE, BY ADENOVIRUS VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PORCINE VACCINES MARKET SIZE, BY ADENOVIRUS VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PORCINE VACCINES MARKET SIZE, BY ADENOVIRUS VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PORCINE VACCINES MARKET SIZE, BY ADENOVIRUS VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PORCINE VACCINES MARKET SIZE, BY ADENOVIRUS VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PORCINE VACCINES MARKET SIZE, BY ADENOVIRUS VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PORCINE VACCINES MARKET SIZE, BY POXVIRUS VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PORCINE VACCINES MARKET SIZE, BY POXVIRUS VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PORCINE VACCINES MARKET SIZE, BY POXVIRUS VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PORCINE VACCINES MARKET SIZE, BY POXVIRUS VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PORCINE VACCINES MARKET SIZE, BY POXVIRUS VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PORCINE VACCINES MARKET SIZE, BY POXVIRUS VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PORCINE VACCINES MARKET SIZE, BY CLASSICAL SWINE FEVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PORCINE VACCINES MARKET SIZE, BY CLASSICAL SWINE FEVER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PORCINE VACCINES MARKET SIZE, BY CLASSICAL SWINE FEVER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PORCINE VACCINES MARKET SIZE, BY CLASSICAL SWINE FEVER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PORCINE VACCINES MARKET SIZE, BY CLASSICAL SWINE FEVER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PORCINE VACCINES MARKET SIZE, BY CLASSICAL SWINE FEVER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PORCINE VACCINES MARKET SIZE, BY ERYSIPELAS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PORCINE VACCINES MARKET SIZE, BY ERYSIPELAS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PORCINE VACCINES MARKET SIZE, BY ERYSIPELAS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PORCINE VACCINES MARKET SIZE, BY ERYSIPELAS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PORCINE VACCINES MARKET SIZE, BY ERYSIPELAS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PORCINE VACCINES MARKET SIZE, BY ERYSIPELAS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PORCINE VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PORCINE VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PORCINE VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PORCINE VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PORCINE VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PORCINE VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PORCINE VACCINES MARKET SIZE, BY SWINE INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PORCINE VACCINES MARKET SIZE, BY SWINE INFLUENZA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PORCINE VACCINES MARKET SIZE, BY SWINE INFLUENZA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PORCINE VACCINES MARKET SIZE, BY SWINE INFLUENZA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PORCINE VACCINES MARKET SIZE, BY SWINE INFLUENZA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PORCINE VACCINES MARKET SIZE, BY SWINE INFLUENZA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL PORCINE VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL PORCINE VACCINES MARKET SIZE, BY COMMERCIAL FARM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL PORCINE VACCINES MARKET SIZE, BY COMMERCIAL FARM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL PORCINE VACCINES MARKET SIZE, BY COMMERCIAL FARM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL PORCINE VACCINES MARKET SIZE, BY COMMERCIAL FARM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL PORCINE VACCINES MARKET SIZE, BY COMMERCIAL FARM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL PORCINE VACCINES MARKET SIZE, BY COMMERCIAL FARM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL PORCINE VACCINES MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL PORCINE VACCINES MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL PORCINE VACCINES MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL PORCINE VACCINES MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL PORCINE VACCINES MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL PORCINE VACCINES MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL PORCINE VACCINES MARKET SIZE, BY SMALLHOLDER FARM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL PORCINE VACCINES MARKET SIZE, BY SMALLHOLDER FARM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL PORCINE VACCINES MARKET SIZE, BY SMALLHOLDER FARM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL PORCINE VACCINES MARKET SIZE, BY SMALLHOLDER FARM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL PORCINE VACCINES MARKET SIZE, BY SMALLHOLDER FARM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL PORCINE VACCINES MARKET SIZE, BY SMALLHOLDER FARM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL PORCINE VACCINES MARKET SIZE, BY VETERINARY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL PORCINE VACCINES MARKET SIZE, BY VETERINARY HOSPITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL PORCINE VACCINES MARKET SIZE, BY VETERINARY HOSPITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL PORCINE VACCINES MARKET SIZE, BY VETERINARY HOSPITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL PORCINE VACCINES MARKET SIZE, BY VETERINARY HOSPITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL PORCINE VACCINES MARKET SIZE, BY VETERINARY HOSPITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRADERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRADERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRADERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRADERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRANASAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRANASAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRANASAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL PORCINE VACCINES MARKET SIZE, BY INTRANASAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL PORCINE VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL PORCINE VACCINES MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL PORCINE VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL PORCINE VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL PORCINE VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL PORCINE VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL PORCINE VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL PORCINE VACCINES MARKET SIZE, BY ATTENUATED LIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL PORCINE VACCINES MARKET SIZE, BY ATTENUATED LIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL PORCINE VACCINES MARKET SIZE, BY ATTENUATED LIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL PORCINE VACCINES MARKET SIZE, BY ATTENUATED LIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL PORCINE VACCINES MARKET SIZE, BY ATTENUATED LIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL PORCINE VACCINES MARKET SIZE, BY ATTENUATED LIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL PORCINE VACCINES MARKET SIZE, BY KILLED WHOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL PORCINE VACCINES MARKET SIZE, BY KILLED WHOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL PORCINE VACCINES MARKET SIZE, BY KILLED WHOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL PORCINE VACCINES MARKET SIZE, BY KILLED WHOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL PORCINE VACCINES MARKET SIZE, BY KILLED WHOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL PORCINE VACCINES MARKET SIZE, BY KILLED WHOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL PORCINE VACCINES MARKET SIZE, BY DNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL PORCINE VACCINES MARKET SIZE, BY DNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL PORCINE VACCINES MARKET SIZE, BY DNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL PORCINE VACCINES MARKET SIZE, BY DNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL PORCINE VACCINES MARKET SIZE, BY DNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL PORCINE VACCINES MARKET SIZE, BY DNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL PORCINE VACCINES MARKET SIZE, BY BACTERIA EXPRESSED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL PORCINE VACCINES MARKET SIZE, BY BACTERIA EXPRESSED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL PORCINE VACCINES MARKET SIZE, BY BACTERIA EXPRESSED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL PORCINE VACCINES MARKET SIZE, BY BACTERIA EXPRESSED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL PORCINE VACCINES MARKET SIZE, BY BACTERIA EXPRESSED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL PORCINE VACCINES MARKET SIZE, BY BACTERIA EXPRESSED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL PORCINE VACCINES MARKET SIZE, BY INSECT CELL EXPRESSED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL PORCINE VACCINES MARKET SIZE, BY INSECT CELL EXPRESSED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL PORCINE VACCINES MARKET SIZE, BY INSECT CELL EXPRESSED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL PORCINE VACCINES MARKET SIZE, BY INSECT CELL EXPRESSED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL PORCINE VACCINES MARKET SIZE, BY INSECT CELL EXPRESSED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL PORCINE VACCINES MARKET SIZE, BY INSECT CELL EXPRESSED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL PORCINE VACCINES MARKET SIZE, BY YEAST EXPRESSED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL PORCINE VACCINES MARKET SIZE, BY YEAST EXPRESSED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL PORCINE VACCINES MARKET SIZE, BY YEAST EXPRESSED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL PORCINE VACCINES MARKET SIZE, BY YEAST EXPRESSED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL PORCINE VACCINES MARKET SIZE, BY YEAST EXPRESSED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL PORCINE VACCINES MARKET SIZE, BY YEAST EXPRESSED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL PORCINE VACCINES MARKET SIZE, BY RNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL PORCINE VACCINES MARKET SIZE, BY RNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL PORCINE VACCINES MARKET SIZE, BY RNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL PORCINE VACCINES MARKET SIZE, BY RNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL PORCINE VACCINES MARKET SIZE, BY RNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL PORCINE VACCINES MARKET SIZE, BY RNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL PORCINE VACCINES MARKET SIZE, BY VLP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL PORCINE VACCINES MARKET SIZE, BY VLP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL PORCINE VACCINES MARKET SIZE, BY VLP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL PORCINE VACCINES MARKET SIZE, BY VLP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL PORCINE VACCINES MARKET SIZE, BY VLP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL PORCINE VACCINES MARKET SIZE, BY VLP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL PORCINE VACCINES MARKET SIZE, BY EMULSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL PORCINE VACCINES MARKET SIZE, BY EMULSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL PORCINE VACCINES MARKET SIZE, BY EMULSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL PORCINE VACCINES MARKET SIZE, BY EMULSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL PORCINE VACCINES MARKET SIZE, BY EMULSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL PORCINE VACCINES MARKET SIZE, BY EMULSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIQUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIQUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIQUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIQUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL PORCINE VACCINES MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL PORCINE VACCINES MARKET SIZE, BY LYOPHILIZED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL PORCINE VACCINES MARKET SIZE, BY LYOPHILIZED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL PORCINE VACCINES MARKET SIZE, BY LYOPHILIZED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL PORCINE VACCINES MARKET SIZE, BY LYOPHILIZED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL PORCINE VACCINES MARKET SIZE, BY LYOPHILIZED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL PORCINE VACCINES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL PORCINE VACCINES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS PORCINE VACCINES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS PORCINE VACCINES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS PORCINE VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 301. AMERICAS PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. AMERICAS PORCINE VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. AMERICAS PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 304. AMERICAS PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 305. AMERICAS PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 306. AMERICAS PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 307. AMERICAS PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2018-2024 (USD MILLION)
  • TABLE 308. AMERICAS PORCINE VACCINES MARKET SIZE, BY CONVENTIONAL, 2025-2032 (USD MILLION)
  • TABLE 309. AMERICAS PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2024 (USD MILLION)
  • TABLE 310. AMERICAS PORCINE VACCINES MARKET SIZE, BY RECOMBINANT, 2025-2032 (USD MILLION)
  • TABLE 311. AMERICAS PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 312. AMERICAS PORCINE VACCINES MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 318. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 319. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2024 (USD MILLION)
  • TABLE 320. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2025-2032 (USD MILLION)
  • TABLE 321. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY MRNA, 2018-2024 (USD MILLION)
  • TABLE 322. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY MRNA, 2025-2032 (USD MILLION)
  • TABLE 323. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2018-2024 (USD MILLION)
  • TABLE 324. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY SUBUNIT, 2025-2032 (USD MILLION)
  • TABLE 325. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2018-2024 (USD MILLION)
  • TABLE 326. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY VIRUS VECTORED, 2025-2032 (USD MILLION)
  • TABLE 327. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
  • TABLE 328. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY DISEASE INDICATION, 2025-2032 (USD MILLION)
  • TABLE 329. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 332. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 333. NORTH AMERICA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 334. NORTH AMERICA PORCINE VACC